# Mucinous Cystadenocarcinoma of Ovary: 10 Years Experience of a Tertiary Cancer Institute, ahpgic

**Manoranjan mohapatra[1], Agniv sarkar[2], Ashok padhy[3], Janmejaya Mohapatra[4], Bhagyalaxmi Nayak[5], Jita parija[6], Smruti sudha Pattnaik[7*]**

[1234567] *Manoranjan Mahapatra, M.D O&G,Gynaeoncologist, Assit prof. Department of Gynaecology Oncology ahpgic*

*Corresponding author; Email: drsmrutisudhapattnaik@gmail.com*

**ABSTRACT:** To calculate the incidence of mucinous cystadenocarcinoma of ovary in the institute and to analyze the preop, intraop and post op characteristics and analyzing the disease free survival disease free survival(dfs) and overall survival (OS )of the cases.It is a retrospective study done in the institute consisting of patients between 2009-2019. Eligibility criteria includes histopathologically and IHC diagnosed Primary mucinous cystadenocarcinoma of ovary. Secondary ovarian mucinous and borderline ovarian mucinous were excluded. Kaplan meyesrs survival methodand regression analysis was used. Both the regimen has similar chemo response rate.Median DFS for stage 1c3 was 52 months and that of advanced stage is 16 months. 4 years DFS was 85.14% for stage 1c3. As only 4 patients died and that too off stage IIIC hence OS for 1c cannot be calculated all the cases should have preoperative endoscopy colonoscopy mammography chest x ray and pap smear to look for other primaries. Both subacute intestinal obstruction and Surgical site infection were seen in 20% cases. The results of the regression analysis. Where, the dependent variable is Recurrence and independent Variables are age, tobacco, pathology, from the analysis we can see that p-values for all the independent Variables are more than 0.05. hence none of the independent factor are significantly associated with recurrence.

**Keywords:** Mucinous Cystadenocarcinoma Tertiary Cancer Disease free Survival

## 1. Introduction

Mucinous cystadenoma is a type of epithelial ovarian carcinoma. Previously it accounted for 12% of all ovarian carcinoma; however after pathological review the recent statistics suggest the amount to be around 3%[1]. 80-85% of mucinous carcinoma are secondaries where primary origin is mostly appendix or other parts of bowel. Mucinous cystadenoma is also a rare gynecological malignancies.[2] For its diagnosis IHC is of paramount importance.primary treatment is mostly similar to other EOC of ovary.[3] However the role of lymphadnectomy and appendicectomy is controversial. Pathologically

it has two variant namely expansile and infiltrative variety.  Infiiltrative  variety is rare and worse prognosis. Various chemo regime has been tried like FOLFOX and XELOX regime however overall response rate is only 30% which is lower than that of response to to serous carcinoma by pacli carbo regime. Survival of mucinous is better in early stages however in advanced cases it is having worse prognosis.



Fig-1 Hps- primary mucinous adenocarcinoma of ovary



Fig -2 Ck-7 +ve primary mucinous adenocarcinoma of ovary

Table1Clinical and Diagnostic Statistics of mucinous adenocarcinoma of the Ovary

| Variables | Values: n (%) |
|---|---|
| Total Cases (N) | 62 |
| Age (in years) | |
| Mean ± SD | 40.73 ± 4.07 |
| Median | 41.50 |
| Mode | 42 |
| Range (Max–Min) | 18 (48–30) |
| Age Groups | |
| 20-40 | 25 (40.32%) |
| 40-60 | 37 (59.68%)) |
| BMI | |
| Mean ± SD | 21.03 ± 1.68 |
| Median | 21.50 |
| Mode | 21.60 |
| Range (Max–Min) | 8.4 (25.4–17) |
| BMI Groups | |
| 15-20 | 14 (22.58%) |
| 20-25 | 47 (75.81%) |
| 25-30 | 01 (1.61%) |
| Tobacco | |
| Addicted | 13 (21%) |
| Not addicted | 49 (79%) |
| Symptoms | |
| Present | 49 |
| Abdominal dist. | 39 (79.59%) |
| Pain Abdomen | 10 (20.41%) |
| Absent | 13 |
| Pre-op albumin level | |
| Mean ± SD | 2.45 ± 0.47 |
| Median | 2.50 |
| Mode | 2.60 |
| Range (Max–Min) | 3.23 (3.50–0.27) |
| Pre-op albumin level Groups | |
| 0-1 | 01 (1.61%) |
| 1-2 | 04 (6.45%) |
| 2-3 | 49 (79.03%) |
| 3-4 | 08 (12.91) |
| Cytoreduction | |
| Lymphadenectomy | |
| Done | 13 (20.97%) |
| Not done | 49 (79.03%) |
| Appendicectomy | |

| | |
|---|---|
| Done | 11 (17.74%) |
| Not done | 51 (82.26%) |
| PCI Score | |
| Mean ± SD | 2.08 ± 1.79 |
| Median | 2 |
| Mode | 0 |
| Range (Max–Min) | 7 (7–0) |

| Variables | Values: n (%) |
|---|---|
| PCI Groups. | |
| 0-2 | 38 (61.3%) |
| 2-4 | 17 (27.4%) |
| 4-6 | 06 (09.7%) |
| 6-8 | 01 (1.6%) |
| CC Score | |
| Mean ± SD | 0.39 ± 0.61 |
| CC-0 | 41 (66.13%) |
| CC-1 | 19 (30.64) |
| CC-2 | 01 (1.6%) |
| CC-3 | 01 (1.6%) |
| Stageing | |
| Stage-1 | 45 (72.58%) |
| 1A | 22 |
| 1C1 | 07 |
| 1C3 | 16 |
| Stage-2 | 05 (08.06%) |
| Stage-3 | 12 (19.35%) |
| Sub-Acute obstructon | |
| SAIO | 13 (21%) |
| Surgical | 49 (79%) |
| Median Blood Loss | |
| Mean ± SD | 1.4 |
| Median | 1.5 |
| Mode | 1.5 |
| Range (Max–Min) | 1.9 (2.3-0.4) |
| Adjuvant chemo | |
| Loss to follow-up | 06 (15.00%) |
| IC3 | 01 |
| II | 02 |
| IIIC | 03 |
| Death | 04 (10.00%) |
| Survive | 30   75.00 %) |

Fertility sparing surgery (USO+SURGICAL STAGING) in 23 cases (37%)

Omental positivity in 12 cases of stage IIIC. Positivity rate was 20%.

Serum  CEA level was elevated in 28 cases( 45.1%).

Median size of the mass was 12 cm

### Regression Analysis

|  | coef | exp(coef) | se(coef) | z | p-value |
|---|---|---|---|---|---|
| age | -0.01792 | 0.9822 | 0.06654 | -0.269 | 0.788 |
| tobacco | -0.5003 | 0.6063 | 0.7689 | -0.651 | 0.515 |
| pathology | -0.1934 | 0.0000 | 9560 | -0.002 | 0.998 |

**Table-2**

|  | B | Exp(B) | S.E. |  | Sig. (p-Value) |
|---|---|---|---|---|---|
| age | -.021 | .980 | .079 |  | .796 |
| tobacco(1) | -.545 | .580 | .860 |  | .526 |
| pathology(1) | -20.122 | .000 | 12090.987 |  | .999 |
| Constant | -.134 | .874 | 3.237 |  | .967 |

**Table -3**

The above table shows the results of the  regression analysis.Where, the dependent variable is Recurrence and independent Variablesare age, tobacco, pathology.From the above analysis we can see that p-values for all the independent Variablesare more than 0.05. hence none of the independent factor are significantly associated with reoccurrence.

**Table4**

| Correlations |  |  |  |  |
|---|---|---|---|---|
|  |  | SAIO | albumin | BLOOD LOSS |
| SAIO | Pearson Correlation | 1 | -.111 | -.177 |
|  | Sig. (2-tailed) |  | .390 | .168 |
| albumin | Pearson Correlation | -.111 | 1 | .069 |
|  | Sig. (2-tailed) | .390 |  | .594 |
| BLOOD LOSS | Pearson Correlation | -.177 | .069 | 1 |
|  | Sig. (2-tailed) | .168 | .594 |  |

**Table5**

**Correlations**

| | | SSI | albumin | Blood Loss |
|---|---|---|---|---|
| SSI | Pearson Correlation | 1 | -.088 | .003 |
| | Sig. (2-tailed) | | .494 | .979 |
| albumin | Pearson Correlation | -.088 | 1 | .069 |
| | Sig. (2-tailed) | .494 | | .594 |
| Blood Loss | Pearson Correlation | .003 | .069 | 1 |
| | Sig. (2-tailed) | .979 | .594 | |

**Correlations**

| | | SSI | SAIO | albumin | Blood Loss |
|---|---|---|---|---|---|
| SSI | Pearson Correlation | 1 | .440** | -.088 | .003 |
| | Sig. (2-tailed) | | .000 | .494 | .979 |
| SAIO | Pearson Correlation | .440** | 1 | -.111 | -.177 |
| | Sig. (2-tailed) | .000 | | .390 | .168 |
| albumin | Pearson Correlation | -.088 | -.111 | 1 | .069 |
| | Sig. (2-tailed) | .494 | .390 | | .594 |
| Blood Loss | Pearson Correlation | .003 | -.177 | .069 | 1 |
| | Sig. (2-tailed) | .979 | .168 | .594 | |
| **. Correlation is significant at the 0.01 level (2-tailed). | | | | | |

**Table 6**

| Mean | | | |
|---|---|---|---|
| | | 95% Confidence Interval | |
| Estimate | Std. Error | Lower Bound | Upper Bound |
| 51.919 | 2.167 | 47.672 | 56.166 |

Recuurence Hazard Function

Mean Survival Time

| Mean Survival Time | | | |
|---|---|---|---|
| Estimate | Std. Error | 95% Confidence Interval | |
| | | Lower Bound | Upper Bound |
| 53.879 | 1.957 | 50.043 | 57.716 |

## DISCUSSION

Overall incidence was 2.98% which is comparable to recent studies. Most common in reproductive age group (median 41.5 yrs.)Early stages( stage 1) comprised 72.5% cases which indicates that mucinous carcinoma have less propensity to be diagnosed at late stage than HGSC[4,5] . Tobacco addiction was seen in 20% cases. In 96% cases optimal cytoreduction were achieved ( CC0+CC1). Lymphadenectomy was done in 20% cases precisely due to enlarged node. Routinely lymph node positivity is only 2-3% in mucinous carcinoma hence it is not recommended[6]. However recent studies have shown that in infiltrative variety of Mucinous carcinoma lymph node positivity can go upto 30% hence there may be a role of lymphadenectomy be present. Similarly appendicectomy was done in 17% cases. Routine appendicectomy is not needed if appendix looks healthy[7,8]. All the cases should have preoperative endoscopy colonoscopy mammography chest x ray and pap smear to look for other primaries. Both subacute intestinal obstruction and Surgical site infection were seen in 20% cases. Adjuvant is required from stage 1c onwards; however recent ESGO guidelines suggest even in 1A with infiltrative variety should get chemo[9]. Both Paclitaxel carboplatin combination and FOLFOX

combination can be used in mucinous carcinoma although pacli carbo  has lower response rate compared to HGSC( 30% vs 80%).[10]

Both the regimen has similar chemo response rate.Median DFS for stage 1c3 was 52 months and that of advanced stage is 16 months. 4 years DFS was 85.14% for stage 1c3.   As only 4 patients died and that too off stage IIIC hence OS for 1c cannot be calculated.

## Conclusion

The disease mostly presents at early stage and reproductive age group. Early diagnosis and optimal cytoreduction is paramount for survival. Advanced stage disease have worse prognosis compared to HGSC.Paclitaxel carboplatin can be used as adjuvant chemo in stage 1c, II, III.

## CONFLICTS OF INTEREST
There are no conflicts to declare.

## REFERENCES
1.Yeika EV, Efie DT, Tolefac PN, Fomengia JN. Giant ovarian cyst masquerading as a massive ascites: a case report. BMC Res Notes. 2017;10(1):749

2. Pilone V, Tramontano S, Picarelli P, Monda A, Romano M, Renzulli M, et al. Giant mucinous ovarian borderline tumor. A good lesson from an asymptomatic case. Int J Surg Case Rep. 2018;50:25–7.

3. Levine DA, Dizon DS, Yashar CM, et al. Handbook for principles and practice of gynecologic oncology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2015.

4. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16(6):389

5. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM.
Unmasking the complexities of mucinous ovarian carcinoma. Gynecol
Oncol. 2010;117(3):491–6.

6. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42(5):677–80.

7. Deligeoroglou E, Eleftheriades M, Shiadoes V, Botsis D, Hasiakos D,
Kontoravdis A, et al. Ovarian masses during adolescence: clinical,
ultrasonographic and pathologic findings, serum tumor markers and
endocrinological profile. Gynecol Endocrinol. 2004;19(1):1–8.

8. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, etal. Evaluation of a risk of malignancy index based on serum CA125,ultrasound findings and menopausal status in the pre-operative diagnosisof pelvic masses. Br J Obstet Gynaecol. 1996;103(8):826–31.

9. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A,BastBDR92102 RC Jr, et al. Serum biomarker panels for the discrimination ofbenign from malignant cases in patients with an adnexal mass. GynecolOncol. 2010;117(3):440–5.

10. Leibman AJ, Kruse B, McSweeney MB. Transvaginal sonography: comparisonwith transabdominal sonography in the diagnosis of pelvic masses. AJR Am
J Roentgenol. 1988;151(1):89–92.